Satellite activites

Sponsored Scientific Satellite activities

Industry Satellite Symposia and Workshop activities as well as non-commercial symposia had dedicated time slots during the WCC 2008:

• before the congress opened in the afternoons (Pre-Congress activities)
• in the middle of the day during the congress (Inter-Sessions)
• at the end of the afternoon (Evening Sessions)

These sessions included:
• Symposia specifically designed for any company active in the field of cardiology as an opportunity to showcase the latest developments and scientific information.

• Workshops designed for medical device companies, biotechnology companies and the distribution sector related to cardiovascular medicine.

• Non-commercial Symposia tailor-made for institutions such as hospitals, universities and not-for-profit organizations.


Please see below a list of sessions that had submitted by the following companies:

Satellite symposia

Abbott Cardiovascular Laboratories
• Acute heart failure treatment: Doing what comes naturally?

AstraZeneca
• Optimizing outcomes in acute coronary syndromes: Role of new approaches to platelet inhibition

Bayer Schering Pharma AG
• Management of right ventricular dysfunction in pulmonary arterial hypertension
• Targeting multiple risk factors to optimize cardiovascular care

Boehringer Ingelheim Pharmaceuticals GmbH
• Acute myocardial infarction: Reperfusion strategies in real life and their potential benefit for the patient
• ONTARGET: New evidence in total cardio and vascular protection

Boston Scientific
• Drug Eluting Stent Technology: a breakthrough in PTCA patient outcome

Colgate Palmolive
• Oral health - cardiovascular health: Emerging evidence of the relationship

Daiichi Sankyo
• Blood pressure and beyond – ancillar effects by AT1 – receptor blockade

GlaxoSmithKline
• Clinical evidence of Fondaparinux in thrombosis: From VTE prevention to acute coronary syndrome treatment
• Diabetes, cardiovascular disease and thiazelidinediones

Janssen Cilag Pharmaceuticals
• Building new strategies in acute decompensated heart failure
 
Menarini International Operations Luxembourg S.A.
• Form hypertension to heart failure: The developing role of vasodilating beta-blockers

Merck KGaA/Serono
• The weight of the evidence: Setting the standard with beta-blockade

Merck, Sharp & Dohme
• ER Niacin/Laropiprant: A new paradigm in comprehensive lipid management

Novartis Pharmaceuticals Corporation
• Emerging data in the treatment of cardiovascular disease

Pfizer
• A Remarkable Change in Smoking Cessation: Approach and Treatment

Sanofi aventis GmbH
• Reshaping the future in the management of atrial fibrillation
• LMWHs across the spectrum of ACS: The Weight of the Evidence

Sanofi aventis Latin America
• Intra-abdominal obesity and cardio-metabolic risk factors: Present and future

Solvay Pharmaceuticals GmbH
• Retinopathy associated with prevalent CHD in patients with T2D: What needs to be done?


How-to Workshop

Biotronik
• New trends in catheter ablation of atrial fibrillation


Non-commercial symposia

American Heart Association
• Strengthening the chain of survival? From bench to community

International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
• Transparency around clinical trials and data: Are we on the right trajectory?